Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 theranostic study of gallium-68 dotatate PET/CT and lutetium-177 oxodotreotide versus long-acting octreotide in SSTR-positive GEP-NETs
CTR20234235Phase 3Active
- Sponsor
- Beijing Atomic High-tech
- Start
- Dec 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Beijing Atomic High-tech. Started Dec 2023; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20234235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234235.